Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Signs up Asia Pacific Distributor

NEW YORK (GenomeWeb News) – Molecular diagnostics company Response Genetics said today that it has tapped the Australian firm Genetic Technologies to distribute three of its oncology testing panels in Southeast Asia and in Australia.

The agreement makes Genetic Technologies the exclusive distributor for the three ResponseDX tests, including the Colon, Lung, and Gastric genetic panels, in Australia, Indonesia, Malaysia, the Philippines, Singapore, and Thailand.

The ResponseDX tests are PCR-based and they analyze gene expression in tumors that correlate with common chemotherapy drugs.

"Based on encouraging sales and rapid adoption here in the Unites States, we have embarked on a growth strategy focused on expanding the availability of our tests in additional markets," Response Genetics CEO Kathleen Danenberg said in a statement.

All of Los Angeles-based Response Genetics' tests are performed through its CLIA-certified lab, and through clinical reference lab NeoGenomics Laboratories.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.